Helius Medical Reports Preliminary Results From PoNSTEP Study, Showing Adherence To PoNS Therapy Improves Gait Deficit In Multiple Sclerosis Patients, Full Results Expected Early 2025
Portfolio Pulse from Benzinga Newsdesk
Helius Medical Technologies has reported preliminary results from its PoNSTEP study, indicating that adherence to PoNS therapy improves gait deficits in multiple sclerosis patients. Full results are expected by early 2025.
September 30, 2024 | 12:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Helius Medical Technologies' preliminary results from the PoNSTEP study show promising improvements in gait deficits for MS patients using PoNS therapy. This could positively impact the company's stock as it indicates potential product efficacy.
The preliminary results suggest that PoNS therapy is effective in improving gait deficits in MS patients, which is a positive development for Helius Medical Technologies. This could lead to increased investor confidence and a potential rise in stock price as the therapy shows promise. The anticipation of full results in 2025 adds to the potential for future positive impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90